Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
GM Blumenthal
Observed names:
G. Blumenthal,
G. M. Blumenthal
Institution:
Merck & Co., Inc., Rahway, NJ, USA (United States)
Observed institutions:
Merck & Co., Inc., Rahway, NJ, USA (United States),
United States Food and Drug Administration,
Center for Drug Evaluation and Research
OpenAlex ID:
A5074943987
The role of nonrandomized trials in the evaluation of oncology drugs
2015
·
R Simon
, GM Blumenthal
, et al.
·
Clinical Pharmacology & Therapeutics
·
71
Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium
2017
·
RL Grossman
, B Abel
, et al.
·
Clinical Pharmacology & Therapeutics
·
49
PDF
Drug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing Science
2017
·
GM Blumenthal
, KB Goldberg
, et al.
·
Clinical Pharmacology & Therapeutics
·
18
Cancer Therapy: Shooting for the Moon
2017
·
JSH Lee
, GM Blumenthal
, et al.
·
Clinical Pharmacology & Therapeutics
·
5
PDF
Leveraging Genomic Factors to Improve Benefit–Risk
2017
·
RN Schuck
, R Charlab
, et al.
·
Clinical and Translational Science
·
5
PDF
FDA evaluation of hepatotoxicity related to tyrosine kinase inhibitors.
2011
·
J. Chang
, M. Rand
, et al.
·
Journal of Clinical Oncology
·
4
1949P Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) for treatment-naïve advanced PD-L1-positive NSCLC: Results from the phase II MK-2870-003/SKB264-II-04 study
2025
·
W.F. Fang
, W. Yao
, et al.
·
Annals of Oncology
·
1
US Food and Drug Administration
2019
·
G. Blumenthal
·
Journal of Thoracic Oncology
·
1
PDF
Key drug development features in the design of early-phase oncology trials: An FDA perspective.
2011
·
R. Charlab Orbach
, G. M. Blumenthal
, et al.
·
Journal of Clinical Oncology
Early targeted drug development: Pilot FDA review of PI3K inhibitor phase I studies using a knowledge management database.
2011
·
G. M. Blumenthal
, R. Charlab Orbach
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
10
Citation count:
154
H-index:
5
I10-index:
3
Year
Topic
Type